---
document_datetime: 2026-01-28 16:22:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/koselugo.html
document_name: koselugo.html
version: success
processing_time: 0.1226087
conversion_datetime: 2026-01-29 12:27:39.629015
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Koselugo

[RSS](/en/individual-human-medicine.xml/67450)

##### Authorised

This medicine is authorised for use in the European Union

selumetinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Koselugo](#news-on)
- [More information on Koselugo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Koselugo is a medicine used to treat plexiform neurofibromas, benign (non-cancerous) tumours along the nerves, when they cause symptoms and cannot be removed by surgery in adults and children from 3 years of age with neurofibromatosis type 1 (NF1).

NF1 is rare, and Koselugo was designated an 'orphan medicine' (a medicine used in rare diseases) on 31 July 2018. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu3182050](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182050) .

Koselugo contains the active substance selumetinib.

Expand section

Collapse section

## How is Koselugo used?

Koselugo is available as capsules and can only be obtained with a prescription. Treatment should be started by a doctor experienced in the diagnosis and treatment of tumours caused by NF1.

The medicine is taken twice a day, about 12 hours apart. It should not be given to patients who cannot swallow the capsule whole.

Before and during treatment with Koselugo, the doctor will check how well the patient's heart, eyes and liver are working. Treatment should be continued for as long as the patient improves or remains stable and the side effects are tolerable. The doctor may reduce the dose or stop treatment temporarily or permanently if certain side effects occur.

For more information about using Koselugo, see the package leaflet or contact your doctor or pharmacist.

## How does Koselugo work?

The active substance in Koselugo, selumetinib, blocks enzymes (proteins) called MEK1 and MEK2 which are involved in stimulating cells to grow. MEK1 and MEK2 are overactive in NF1, making tumour cells grow uncontrollably. By blocking these enzymes, selumetinib helps slow down the growth of the tumour cells.

## What benefits of Koselugo have been shown in studies?

Two main studies found that Koselugo is effective at treating plexiform neurofibromas in children and adults with NF1 by shrinking the size of these tumours. The main measure of effectiveness in both studies was the proportion of patients who responded to treatment with Koselugo. Patients were considered to have responded when there were no signs of tumours (complete response) or when tumours shrank by at least 20% in size (partial response), and the response was confirmed within 3 to 6 months.

In the first study, tumour size decreased by at least 20% in 33 out of 50 (66%) children aged 3 years and older with NF1 and plexiform neurofibromas that could not be removed by surgery. In this study, Koselugo was not compared with any other medicine or placebo (a dummy treatment).

In the second study involving 145 adults with NF1 and plexiform neurofibromas, tumour size decreased by at least 20% in 14 out of 71 (around 20%) people who received Koselugo, compared with 4 out of 74 (around 5%) of those given placebo.

## What are the risks associated with Koselugo?

For the full list of side effects and restrictions with Koselugo, see the package leaflet.

The most common side effects with Koselugo in children (which may affect more than 4 in 10 people) include vomiting, rash, increased blood creatine phosphokinase (an enzyme released into the blood when muscle is damaged), diarrhoea, nausea (feeling sick), stomatitis (inflammation of the lining of the mouth), asthenic events (feeling weak), dry skin, fever, acneiform dermatitis (a rash resembling acne), hypoalbuminaemia (low levels of albumin, a blood protein), increased aspartate aminotransferase (an enzyme indicating a possible sign of liver problems), decreased haemoglobin (the protein in red blood cells that carries oxygen around the body) and paronychia (nail bed infection).

Some side effects with Koselugo in children can be serious. The most frequent (which may affect up to 1 in 10 people) include diarrhoea, anaemia (low red blood cell count), fever, increased blood creatine phosphokinase, increased blood creatinine (a sign of kidney problems), peripheral oedema (swelling especially of the ankles and feet) and vomiting.

The most common side effects with Koselugo in adults (which may affect more than 2 in 10 people) include acneiform rash (a rash resembling acne), increased blood creatine phosphokinase, diarrhoea, rash and vomiting.

Koselugo must not be used in patients with severe liver disease.

## Why is Koselugo authorised in the EU?

Plexiform neurofibromas can cause disfigurement, movement difficulties, pain and nerve problems. Koselugo has been shown to shrink tumour size in adults and children aged 3 years and older with NF1-associated plexiform neurofibromas that cannot be removed by surgery. In terms of safety, Koselugo's side effects are considered manageable.

Koselugo has been given conditional authorisation. This means that it has been authorised on the basis of less comprehensive data than are normally required because it fulfils an unmet medical need. The Agency considers that the benefit of having the medicine available earlier outweighs any risks associated with using it while awaiting further evidence.

The company must provide further data on Koselugo. It must submit the results from an ongoing study to confirm the long-term safety of Koselugo in children with NF1 aged 3 years and older. Every year, the Agency will review any new information that becomes available.

## What measures are being taken to ensure the safe and effective use of Koselugo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Koselugo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Koselugo are continuously monitored. Side effects reported with Koselugo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Koselugo

Koselugo received a conditional marketing authorisation valid throughout the EU on 17 June 2021.

Koselugo : EPAR - Medicine overview

Reference Number: EMA/244286/2021

English (EN) (125.26 KB - PDF)

**First published:** 13/10/2021

**Last updated:** 28/01/2026

[View](/en/documents/overview/koselugo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-665)

български (BG) (152.11 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/bg/documents/overview/koselugo-epar-medicine-overview_bg.pdf)

español (ES) (124.97 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/es/documents/overview/koselugo-epar-medicine-overview_es.pdf)

čeština (CS) (150.68 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/cs/documents/overview/koselugo-epar-medicine-overview_cs.pdf)

dansk (DA) (125.78 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/da/documents/overview/koselugo-epar-medicine-overview_da.pdf)

Deutsch (DE) (128.9 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/de/documents/overview/koselugo-epar-medicine-overview_de.pdf)

eesti keel (ET) (121.82 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/et/documents/overview/koselugo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (148.77 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/el/documents/overview/koselugo-epar-medicine-overview_el.pdf)

français (FR) (126.98 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/fr/documents/overview/koselugo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (146.68 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/hr/documents/overview/koselugo-epar-medicine-overview_hr.pdf)

italiano (IT) (124.44 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/it/documents/overview/koselugo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (157.8 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/lv/documents/overview/koselugo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (146.66 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/lt/documents/overview/koselugo-epar-medicine-overview_lt.pdf)

magyar (HU) (149.46 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/hu/documents/overview/koselugo-epar-medicine-overview_hu.pdf)

Malti (MT) (150.7 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/mt/documents/overview/koselugo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (126.81 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/nl/documents/overview/koselugo-epar-medicine-overview_nl.pdf)

polski (PL) (151.33 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/pl/documents/overview/koselugo-epar-medicine-overview_pl.pdf)

português (PT) (125.58 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/pt/documents/overview/koselugo-epar-medicine-overview_pt.pdf)

română (RO) (144.94 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/ro/documents/overview/koselugo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (148.69 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/sk/documents/overview/koselugo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (146.28 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/sl/documents/overview/koselugo-epar-medicine-overview_sl.pdf)

Suomi (FI) (122.52 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/fi/documents/overview/koselugo-epar-medicine-overview_fi.pdf)

svenska (SV) (123.12 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/sv/documents/overview/koselugo-epar-medicine-overview_sv.pdf)

Koselugo : EPAR - Risk-management-plan summary

English (EN) (444.39 KB - PDF)

**First published:** 13/10/2021

[View](/en/documents/rmp-summary/koselugo-epar-risk-management-plan-summary_en.pdf)

## Product information

Koselugo : EPAR - Product information

English (EN) (395.18 KB - PDF)

**First published:** 13/10/2021

**Last updated:** 28/01/2026

[View](/en/documents/product-information/koselugo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-303)

български (BG) (540.18 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/bg/documents/product-information/koselugo-epar-product-information_bg.pdf)

español (ES) (403.26 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/es/documents/product-information/koselugo-epar-product-information_es.pdf)

čeština (CS) (1.74 MB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/cs/documents/product-information/koselugo-epar-product-information_cs.pdf)

dansk (DA) (372.42 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/da/documents/product-information/koselugo-epar-product-information_da.pdf)

Deutsch (DE) (439.91 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/de/documents/product-information/koselugo-epar-product-information_de.pdf)

eesti keel (ET) (380.9 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/et/documents/product-information/koselugo-epar-product-information_et.pdf)

ελληνικά (EL) (516.71 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/el/documents/product-information/koselugo-epar-product-information_el.pdf)

français (FR) (514.77 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/fr/documents/product-information/koselugo-epar-product-information_fr.pdf)

hrvatski (HR) (479.57 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/hr/documents/product-information/koselugo-epar-product-information_hr.pdf)

íslenska (IS) (395.57 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/is/documents/product-information/koselugo-epar-product-information_is.pdf)

italiano (IT) (502.1 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/it/documents/product-information/koselugo-epar-product-information_it.pdf)

latviešu valoda (LV) (474.2 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/lv/documents/product-information/koselugo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (512.53 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/lt/documents/product-information/koselugo-epar-product-information_lt.pdf)

magyar (HU) (537.06 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/hu/documents/product-information/koselugo-epar-product-information_hu.pdf)

Malti (MT) (502.38 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/mt/documents/product-information/koselugo-epar-product-information_mt.pdf)

Nederlands (NL) (398.6 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/nl/documents/product-information/koselugo-epar-product-information_nl.pdf)

norsk (NO) (397.01 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/no/documents/product-information/koselugo-epar-product-information_no.pdf)

polski (PL) (527.25 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/pl/documents/product-information/koselugo-epar-product-information_pl.pdf)

português (PT) (477.4 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/pt/documents/product-information/koselugo-epar-product-information_pt.pdf)

română (RO) (531.76 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/ro/documents/product-information/koselugo-epar-product-information_ro.pdf)

slovenčina (SK) (464.14 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/sk/documents/product-information/koselugo-epar-product-information_sk.pdf)

slovenščina (SL) (475.4 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/sl/documents/product-information/koselugo-epar-product-information_sl.pdf)

Suomi (FI) (398.46 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/fi/documents/product-information/koselugo-epar-product-information_fi.pdf)

svenska (SV) (405.68 KB - PDF)

**First published:**

13/10/2021

**Last updated:**

28/01/2026

[View](/sv/documents/product-information/koselugo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000245231 24/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Koselugo : EPAR - All authorised presentations

English (EN) (22.27 KB - PDF)

**First published:** 13/10/2021

[View](/en/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-694)

български (BG) (26.34 KB - PDF)

**First published:**

13/10/2021

[View](/bg/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_bg.pdf)

español (ES) (21.5 KB - PDF)

**First published:**

13/10/2021

[View](/es/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (23.06 KB - PDF)

**First published:**

13/10/2021

[View](/cs/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (22.47 KB - PDF)

**First published:**

13/10/2021

[View](/da/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (24.99 KB - PDF)

**First published:**

13/10/2021

[View](/de/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (22.77 KB - PDF)

**First published:**

13/10/2021

[View](/et/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (24.38 KB - PDF)

**First published:**

13/10/2021

[View](/el/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_el.pdf)

français (FR) (23.74 KB - PDF)

**First published:**

13/10/2021

[View](/fr/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (23.95 KB - PDF)

**First published:**

13/10/2021

[View](/hr/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (21.95 KB - PDF)

**First published:**

13/10/2021

[View](/is/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.25 KB - PDF)

**First published:**

13/10/2021

[View](/it/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (22.36 KB - PDF)

**First published:**

13/10/2021

[View](/lv/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (22.62 KB - PDF)

**First published:**

13/10/2021

[View](/lt/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (25.24 KB - PDF)

**First published:**

13/10/2021

[View](/hu/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (25.49 KB - PDF)

**First published:**

13/10/2021

[View](/mt/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (21.59 KB - PDF)

**First published:**

13/10/2021

[View](/nl/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (22.52 KB - PDF)

**First published:**

13/10/2021

[View](/no/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_no.pdf)

polski (PL) (23.6 KB - PDF)

**First published:**

13/10/2021

[View](/pl/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_pl.pdf)

português (PT) (24.51 KB - PDF)

**First published:**

13/10/2021

[View](/pt/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_pt.pdf)

română (RO) (30.16 KB - PDF)

**First published:**

13/10/2021

[View](/ro/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (23.71 KB - PDF)

**First published:**

13/10/2021

[View](/sk/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (21.95 KB - PDF)

**First published:**

13/10/2021

[View](/sl/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (21.09 KB - PDF)

**First published:**

13/10/2021

[View](/fi/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (21.69 KB - PDF)

**First published:**

13/10/2021

[View](/sv/documents/all-authorised-presentations/koselugo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Koselugo Active substance selumetinib sulfate International non-proprietary name (INN) or common name selumetinib Therapeutic area (MeSH) Neurofibromatosis 1

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above

## Authorisation details

EMA product number EMEA/H/C/005244

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

AstraZeneca AB

151 85 Sodertalje

Opinion adopted 22/04/2021 Marketing authorisation issued 17/06/2021 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Koselugo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (148.65 KB - PDF)

**First published:** 28/01/2026

[View](/en/documents/procedural-steps-after/koselugo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Koselugo : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (156.72 KB - PDF)

**First published:** 13/10/2021

**Last updated:** 28/01/2026

[View](/en/documents/procedural-steps-after/koselugo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Koselugo-H-C-005244-X-0018-G : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2387194

English (EN) (6.31 MB - PDF)

**First published:** 28/01/2026

[View](/en/documents/variation-report/koselugo-h-c-005244-x-0018-g-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of positive opinion for Koselugo X-18-G

Adopted

Reference Number: EMA/CHMP/348586/2025

English (EN) (120.1 KB - PDF)

**First published:** 14/11/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-koselugo-x-18-g_en.pdf)

Koselugo-H-C-005244-P46-007 : EPAR - Assessment report

Adopted

Reference Number: EMA/24182/2025

English (EN) (1.06 MB - PDF)

**First published:** 14/03/2025

[View](/en/documents/variation-report/koselugo-h-c-005244-p46-007-epar-assessment-report_en.pdf)

Koselugo-H-C-005244-P46-006 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/478212/2024

English (EN) (991 KB - PDF)

**First published:** 14/03/2025

**Last updated:** 06/10/2025

[View](/en/documents/variation-report/koselugo-h-c-005244-p46-006-epar-assessment-report_en.pdf)

Koselugo-H-C-005244-P46-005 : EPAR - Assessment report

Adopted

Reference Number: EMA/CHMP/478188/2024

English (EN) (1.35 MB - PDF)

**First published:** 14/03/2025

[View](/en/documents/variation-report/koselugo-h-c-005244-p46-005-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Koselugo : EPAR - Public assessment report

Adopted

Reference Number: EMA/549867/2021

English (EN) (7.16 MB - PDF)

**First published:** 13/10/2021

[View](/en/documents/assessment-report/koselugo-epar-public-assessment-report_en.pdf)

Koselugo : Orphan maintenance assessment report

Adopted

Reference Number: EMA/OD/0000033877

English (EN) (271.67 KB - PDF)

**First published:** 12/10/2021

[View](/en/documents/orphan-maintenance-report/koselugo-orphan-maintenance-assessment-report_en.pdf)

CHMP summary of positive opinion for Koselugo

Adopted

Reference Number: EMA/CHMP/210566/2021

English (EN) (103.04 KB - PDF)

**First published:** 23/04/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-koselugo_en.pdf)

#### News on Koselugo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025) 14/11/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 September 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-september-2025) 19/09/2025

#### More information on Koselugo

- [EMEA-001585-PIP01-13-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001585-pip01-13-m06)
- [EU/3/18/2050 - orphan designation for treatment of neurofibromatosis type 1](/en/medicines/human/orphan-designations/eu-3-18-2050)
- [Koselugo - opinion on variation to marketing authorisation](/en/medicines/human/variation/koselugo)

**This page was last updated on** 28/01/2026

## Share this page

[Back to top](#main-content)